The atypical antipsychotic lurasidone (also known as SM-13496) was approved in the United States in 2010 as an oral agent for the treatment of patients with schizophrenia. Lurasidone has potent affinity for D2 (Ki= 1.7 nM) and 5-HT2A (Ki= 2.0 nM) receptors and acts as an antagonist at both receptors. It is also a partial agonist at the 5-HT1A receptor and, unlike other atypical agents, is a potent antagonist at the 5-HT7 receptor; both of these activities are thought to confer beneficial cognitive properties. Lurasidone is further differentiated by its lack of affinity for muscarinic and histamine H1 receptors and its weak affinity for the 5-HT2C receptor. Antagonism at H1 and 5-HT2C receptors has been implicated in weight gain associated with atypical agents, while muscarinic receptor antagonism is associated with cognitive deficits.